Cargando…
The TLR9 ligand CpG ODN 2006 is a poor adjuvant for the induction of de novo CD8(+) T-cell responses in vitro
Toll-like receptor 9 (TLR9) agonists have gained traction in recent years as potential adjuvants for the induction of adaptive immune responses. It has nonetheless remained unclear to what extent such ligands can facilitate the priming events that generate antigen-specific effector and/or memory CD8...
Autores principales: | Papagno, Laura, Kuse, Nozomi, Lissina, Anna, Gostick, Emma, Price, David A., Appay, Victor, Nicoli, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363897/ https://www.ncbi.nlm.nih.gov/pubmed/32669577 http://dx.doi.org/10.1038/s41598-020-67704-0 |
Ejemplares similares
-
Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014) -
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
por: Ito, Sayami, et al.
Publicado: (2020) -
Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model
por: Golali, Ensieh, et al.
Publicado: (2012) -
TLR9-mediated ARF6 activation is involved in advancing CpG ODN cellular uptake
por: Wu, Jing-Yiing, et al.
Publicado: (2012) -
The effect of CpG-ODN on antigen presenting cells of the foal
por: Flaminio, M Julia BF, et al.
Publicado: (2007)